Management of Gastrointestinal and Urogenital (GI/GU) Bleedings in Atrial Fibrillation Patients Using Pradaxa

An Observational Study Assessing the Management of Gastrointestinal and Urogenital Bleeding Events in Patients With Atrial Fibrillation Treated With Dabigatran Etexilate

This study is being conducted to collect data on the management of gastrointestinal and urogenital bleeding events occurring in patients with atrial fibrillation taking dabigatran etexilate.

Purpose:

Inclusion criteria:

• >=18 years of age;
• Confirmed diagnosis of Atrial Fibrillation (AF);
• Documentation that the patient had an acute GI and/or GU bleeding event and having taken at least one dose of dabigatran prior to the event.

Exclusion criteria:

• Confirmed diagnosis of valvular AF (VAF);
• Documentation that the patient was taking dabigatran with other oral anticoagulant;
• Documentation of the patient receiving thrombolytic therapy prior to the event;
• Documentation that the patient was enrolled in an investigational clinical trial at the time of the event;
• Medical record was not available.